Cargando…

DNA Priming for Seasonal Influenza Vaccine: A Phase 1b Double-Blind Randomized Clinical Trial

BACKGROUND: The efficacy of current influenza vaccines is limited in vulnerable populations. DNA vaccines can be produced rapidly, and may offer a potential strategy to improve vaccine immunogenicity, indicated by studies with H5 influenza DNA vaccine prime followed by inactivated vaccine boost. MET...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ledgerwood, Julie E., Bellamy, Abbie R., Belshe, Robert, Bernstein, David I., Edupuganti, Srilatha, Patel, Shital M., Renehan, Phyllis, Zajdowicz, Thad, Schwartz, Richard, Koup, Richard, Bailer, Robert T., Yamshchikov, Galina V., Enama, Mary E., Sarwar, Uzma, Larkin, Brenda, Graham, Barney S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4423975/ https://www.ncbi.nlm.nih.gov/pubmed/25950433 http://dx.doi.org/10.1371/journal.pone.0125914

Ejemplares similares

Safety and immunogenicity of investigational seasonal influenza hemagglutinin DNA vaccine followed by trivalent inactivated vaccine administered intradermally or intramuscularly in healthy adults: An open-label randomized phase 1 clinical trial
por: Carter, Cristina, et al.
Publicado: (2019)

DNA vaccine priming for seasonal influenza vaccine in children and adolescents 6 to 17 years of age: A phase 1 randomized clinical trial
por: Houser, Katherine V., et al.
Publicado: (2018)

Priming Immunization with DNA Augments Immunogenicity of Recombinant Adenoviral Vectors for Both HIV-1 Specific Antibody and T-Cell Responses
por: Koup, Richard A., et al.
Publicado: (2010)

An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trial
por: DeZure, Adam D., et al.
Publicado: (2017)

Homologous Boosting with Adenoviral Serotype 5 HIV Vaccine (rAd5) Vector Can Boost Antibody Responses despite Preexisting Vector-Specific Immunity in a Randomized Phase I Clinical Trial
por: Sarwar, Uzma N., et al.
Publicado: (2014)

P18-06. Increased HIV-specific immunity in HIV-infected individuals vaccinated with a DNA prime, rAd5 boost regimen
por: Casazza, JP, et al.
Publicado: (2009)

DNA Vaccine Delivered by a Needle-Free Injection Device Improves Potency of Priming for Antibody and CD8+ T-Cell Responses after rAd5 Boost in a Randomized Clinical Trial
por: Graham, Barney S., et al.
Publicado: (2013)

Phase 1 Study of Pandemic H1 DNA Vaccine in Healthy Adults
por: Crank, Michelle C., et al.
Publicado: (2015)

Safety and Immunogenicity of DNA Vaccines Encoding Ebolavirus and Marburgvirus Wild-Type Glycoproteins in a Phase I Clinical Trial
por: Sarwar, Uzma N., et al.
Publicado: (2015)

DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials
por: Ledgerwood, Julie E, et al.
Publicado: (2011)

Phase I Randomized Clinical Trial of VRC DNA and rAd5 HIV-1 Vaccine Delivery by Intramuscular (IM), Subcutaneous (SC) and Intradermal (ID) Administration (VRC 011)
por: Enama, Mary E., et al.
Publicado: (2014)

P14-10. Comparable immunogenicity of VRC DNA and rAd5 HIV-1 vaccines delivered by intramuscular, subcutaneous and intradermal routes in healthy adults (VRC 011)
por: Ledgerwood, JE, et al.
Publicado: (2009)

Safety and Immunogenicity of a rAd35-EnvA Prototype HIV-1 Vaccine in Combination with rAd5-EnvA in Healthy Adults (VRC 012)
por: Crank, Michelle C., et al.
Publicado: (2016)

Correlation between herpes simplex virus neutralizing antibody titers determined by ELVIS cell and traditional plaque reduction assays
por: Blevins, Tamara P., et al.
Publicado: (2019)

A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial
por: Martin, Julie E., et al.
Publicado: (2008)

Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults
por: Gaudinski, Martin R., et al.
Publicado: (2018)

Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials
por: Gaudinski, Martin R, et al.
Publicado: (2018)

P14-12. Safety and tolerability of VRC DNA and rAd5 HIV-1 vaccine delivery by intramuscular, subcutaneous and intradermal administration in healthy adults
por: Enama, ME, et al.
Publicado: (2009)

Randomized Clinical Trial to Assess the Impact of the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 on HIV-1 Persistence in Individuals on Effective ART
por: Riddler, Sharon A, et al.
Publicado: (2018)

Differences in HPV-specific antibody Fc-effector functions following Gardasil® and Cervarix® vaccination
por: Roy, Vicky, et al.
Publicado: (2023)

Pericarditis Associated With Acute Zika Virus Infection in a Returning Traveler
por: Waggoner, Jesse J., et al.
Publicado: (2017)

Baseline Levels of Influenza-Specific B Cells and T Cell Responses Modulate Human Immune Responses to Swine Variant Influenza A/H3N2 Vaccine
por: Lai, Lilin, et al.
Publicado: (2020)

Publication practices and attitudes towards evidence-based medicine in central Asia
por: Yamshchikov, Galina V, et al.
Publicado: (2013)

Characterization of SARS-CoV-specific memory T cells from recovered individuals 4 years after infection
por: Fan, Yan-Ying, et al.
Publicado: (2009)

Human memory T cell responses to SARS-CoV E protein
por: Peng, Hui, et al.
Publicado: (2006)

Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjects
por: Frey, Sharon E., et al.
Publicado: (2015)

Long-lived memory T lymphocyte responses against SARS coronavirus nucleocapsid protein in SARS-recovered patients
por: Peng, Hui, et al.
Publicado: (2006)

Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial
por: Tapia, Milagritos D, et al.
Publicado: (2016)

Long-lived effector/central memory T-cell responses to severe acute respiratory syndrome coronavirus (SARS-CoV) S antigen in recovered SARS patients
por: Yang, Li-Tao, et al.
Publicado: (2006)

Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses
por: Precopio, Melissa L., et al.
Publicado: (2007)

Cross-Reactive Antibody Responses to Novel H5Nx Influenza Viruses Following Homologous and Heterologous Prime-Boost Vaccination with a Prepandemic Stockpiled A(H5N1) Vaccine in Humans
por: Levine, Min Z, et al.
Publicado: (2017)

In Response
por: Edupuganti, Srilatha, et al.
Publicado: (2013)

Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates
por: Wille-Reece, Ulrike, et al.
Publicado: (2006)

Effect of Monoclonal Antibody Treatment on Clinical Outcomes in Ambulatory Patients With Coronavirus Disease 2019
por: Anderson, Blake, et al.
Publicado: (2021)

No Clinical Association of Live Attenuated Influenza Virus with Nasal Carriage of Bacteria or Acute Otitis Media
por: Coelingh, Kathleen L., et al.
Publicado: (2014)

Biphasic Zika Illness With Rash and Joint Pain
por: Edupuganti, Srilatha, et al.
Publicado: (2017)

2492. Clinical, Virologic, and Immunologic Characteristics of Zika Virus Infection in a Cohort of US Patients
por: Sahly, Hana M El, et al.
Publicado: (2018)

Primed for Reading
por: Boyd, Robert
Publicado: (2010)

Reconsidering Early HIV Treatment and Supervised Treatment Interruptions
por: Koup, Richard A
Publicado: (2004)

The relative efficacy of trivalent live attenuated and inactivated influenza vaccines in children and adults
por: Ambrose, Christopher S., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_a35bmkca2ta1df5ukkf1se0j98